Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 8/20 | 0.69 |
| ▸ | SLC22A12 | Q96S37 | 9/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | ESRRA | P11474 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4178475 | 0.85 | AR (0.68) | ARSLC22A12L3MBTL1HTR2ASLC6A4 | |
| SCHEMBL4171619 | 0.85 | AR (0.67) | ARSLC22A12MAPTL3MBTL1ESRRA | |
| SCHEMBL17052853 | 0.84 | AR (0.65) | ARSLC22A12HTR2ASLC6A4KCNH2 | |
| SCHEMBL4181860 | 0.83 | AR (0.67) | ARSLC22A12ESRRA | |
| SCHEMBL4163780 | 0.82 | AR (0.72) | ARSLC22A12HTR2ASLC6A4KCNH2 | |
| SCHEMBL4168834 | 0.82 | AR (0.72) | ARSLC22A12HTR2ASLC6A4KCNH2 | |
| SCHEMBL4188129 | 0.81 | AR (1.00) | ARESRRA | |
| SCHEMBL4171318 | 0.81 | AR (0.58) | ARSLC22A12HTR2ASLC6A4KCNH2 | |
| SCHEMBL5501402 | 0.79 | AR (0.53) | ARSLC22A12MAPTRAB9AL3MBTL1 | |
| SCHEMBL14081445 | 0.78 | AR (0.57) | ARSLC22A12HTR2ASLC6A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105349-A1 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2009-04-23 | — | — | US | claimed |
| US-20090105349-A1 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105349-A1 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105349-A1 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2009-04-23 | — | — | US | disclosed |
| EP-1781280-A2 | ANDROGEN MODULATORS | Warner-Lambert Company LLC (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006018723-A2 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105349-A1 | ANDROGEN MODULATORS | AR, NR5A1, SHBG | AR 1/4885SLC22A12 3958/4885MAPT 4570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.